Background/Aims: Bradykinin has been shown to exert a variety of protective effects against vascular injury, and to reduce the levels of several factors involved in the coagulation cascade. A key determinant of thrombin generation is tissue factor (TF). However, whether bradykinin can regulate TF expression remains to be investigated. Methods: To study the effect of bradykinin on TF expression, we used Lipopolysaccharides (LPS) to induce TF expression in human umbilical vein endothelial cells and monocytes. Transcript levels were determined by RT-PCR, protein abundance by Western blotting. In the in vivo study, bradykinin and equal saline were intraperitoneally injected into mice for three days ahead of inferior cava vein ligation that we took to induce thrombus formation, after which bradykinin and saline were injected for another two days. Eventually, the mice were sacrificed and tissues were harvested for tests. Results: Exogenous bradykinin markedly inhibited TF expression in mRNA and protein level induced by LPS in a dose-dependent manner. Moreover, the NO synthase antagonist L-NAME and PI3K inhibitor LY294002 dramatically abolished the inhibitory effects of bradykinin on tissue factor expression. PI3K/Akt signaling pathway activation induced by bradykinin administration reduced the activity of GSK-3β and MAPK, and reduced NF-kB level in the nucleus, thereby inhibiting TF expression. Consistent with this, intraperitoneal injection of C57/BL6 mice with bradykinin also inhibited the thrombus formation induced by ligation 
Animals C57BL/6J mice were purchased from SLAC Laboratory Animal Co, Ltd (Shanghai, China). All procedures were approved by the Animal Research Ethics Board at Huazhong University of Science and Technology and conformed to Directive 2010/63/EU of the European Parliament. Mice were randomly divided into 3 groups: Sham, Model and Bradykinin. Before surgical procedure, the mice of bradykinin group were intraperitoneally injected with bradykinin (10 mg/kg/d) once a day for three days. On the fourth day, after anesthetization by intraperitoneal injection with 60 mg/kg of pentobarbital, the ligation of inferior vena cava (IVC) was executed via a midline laparotomy, dissected at the level of the renal veins, and then ligated below the renal veins as previously described [22] . After ligation, the mice received bradykinin injection for another two days and analgesic therapy was performed using buprenorphine at 0.1 mg/kg body weight for 3 days. The mice in other groups received equal saline as control. Sham animals underwent the same surgical procedures except for IVC ligation. If the dissection was traumatic or the IVC was ruptured during surgery, mice were excluded for further studies. 48 hours later, mice were euthanized by introperitonial injection with 100 mg/kg of pentobarbital, and the thrombosed IVC were collected, weighed, and measured for length after blood sampling [23] . The samples were snap-frozen or stored for histological analysis.
Statistical analysis
All data were shown as mean ± standard deviation (SD). Comparisons between groups were performed by a one-way analysis of ANOVA with post hoc analyses performed using the Student-NewmanKeuls method and the level for significant statistical differences was set at P < 0.05.
Results

Bradykinin suppressed LPS-induced tissue factor expression in HUVECs and human monocytes
To determine whether bradykinin regulates TF expression in endothelial cells, Confluent cells were pretreated with bradykinin at various concentrations for 6 hours, after which LPS was used to induce tissue factor expression. HUVECs were harvested 4 hours after LPS treatment. As expected, LPS significantly induced TF expression in protein and mRNA level in a dose dependent manner in HUVECs as shown in Fig. 1A and 1B. TF expression induced by LPS (1.0 μg/ml) was higher than that induced by LPS (0.1 μg/ml) ( Fig. 1A and 1B ), so LPS (1.0 μg/ml) was used to induce TF expression in the following experiments. As shown in Fig. 1C and 1D , Bradykinin significantly prevented TF expression induced by LPS in protein and mRNA level in a dose dependent manner. In addition, bradykinin (10 -5 mol/l) obviously inhibited TF expression in protein and mRNA level ( Fig. 1C and 1D ), and bradykinin (10 -5 mol/l) was selected to explore the effects of bradykinin on TF expression in the following experiments. Taken together, these data indicated that bradykinin prevented TF expression induced by LPS in HUVECs.
Previous data indicated that monocytes derived TF was also involved in the pathogenesis of deep vein thrombosis [24] . As shown in Fig. 1E and 1F, Bradykinin significantly prevented TF expression induced by LPS in protein and mRNA level in a dose dependent manner in cultured THP-1 cells. Collectively, these data indicated that bradykinin prevented TF expression induced by LPS in monocytes.
The inhibitory effect of bradykinin on tissue factor expression is dependent of PI3K/AKT and MAPK signaling Previous data indicated that PI3K/Akt signaling pathway negatively regulated TF expression in vitro and in vivo [25] . We explored whether bradykinin inhibited LPS-induced TF expression via activating PI3K/Akt signaling pathway. As expected, PI3K inhibitor LY294002 abolished the inhibitory effects of bradykinin on tissue factor expression in HUVECs and monocytes as shown in Fig. 2A and 3A . Furthermore, under resting conditions, bradykinin increased Akt phosphorylation in HUVECs (Fig. 2B) and monocytes (Fig. 3B) . The PI3K inhibitor LY294002 blocked the activation of Akt by bradykinin, indicating that Cellular Physiology and Biochemistry
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Akt phosphorylation in bradykinin-treated cells is attributable to bradykinin-mediated PI3K activation. GSK-3β, a crucial molecule for p65 phosphorylation, is one downstream phosphorylation target of Akt [25] . Bradykinin treatment increased the levels of phosphor-GSK3β in HUVECs and monocytes under both resting and LPS-treated conditions ( Fig. 2C  and 3C ), thus inhibited the disassociation of p65 from IκBα and its translocation to nuclear as Fig. 4B indicated. Extracellular signal-regulated kinase (ERK), an important MAPK for TF expression, is the target of the Raf-1 pathway, the latter is regulated by PI3K/Akt signaling [26] . In HUVECs and monocytes, LPS treatment markedly upregulated phosphor-ERK level, and ERK phosphorylation was significantly inhibited by bradykinin ( Fig. 2E and 2E ). In addition, P38MAPK and JNK phosphorylation was also upregulated by LPS, and moreover, the phosphor-P38MAPK and phosphor-JNK level was also dramatically inhibited by bradykinin in HUVECs and monocytes (Fig. 2D, F and Fig. 3D, F) . Interestingly, PI3K inhibitor LY294002 administration efficiently abolished the effects of bradykinin on phosphor-P38MAPK and phosphor-JNK level as well as TF expression as shown in Fig. 2 and 3 . Thus, the PI3K/Akt pathway is critically involved in the inhibitory effect of bradykinin on TF expression in HUVECs and monocytes. Previous study indicated that transcription factors NF-kB activation was involved in tissue factor expression [27] . We examined whether NF-kB participated in the inhibitory effects of bradykinin on tissue factor expression in HUVECs and monocytes. Interestingly, LPS markedly reduced IkBα expression, and increased nuclear NF-kB level in HUVECs and monocytes, and moreover, bradykinin treatment prevented the decrease in IkBα expression and the increase in nuclear NF-kB level as shown in Fig. 4A , 4B, 4C and 4D. As expected, PI3K inhibitor LY294002 administration significantly and partly abolished the beneficial effects of bradykinin on NF-kB transcriptional activity indirectly characterized by changes in IΚBα and nuclear NF-kB level (Fig. 4A , 4B, 4C and 4D) and subsequent TF expression as shown in Fig. 2A and 3A. Collectively, these data indirectly indicated that bradykinin inhibited tissue factor expression via regulating NF-kB-mediated tissue factor transcription in HUVECs and monocytes.
Bradykinin inhibits tissue factor expression by BK B2 receptor-mediated NO release
Bradykinin receptors are mainly divided pharmacologically into two subtypes, B1 and B2. Previous data indicate that most of the known actions of bradykinin (BK) are mediated via B2 receptors [28] . To check whether the protective effect against tissue factor expression is also dependent on the BK B2 receptor, the effect of the BK B2 receptor antagonist HOE-140 (1 μmol/L) on the reduction of TF expression by BK was explored in HUVECs and monocytes. HOE-140 administration totally blocked the beneficial effect of bradykinin on TF expression, -6 mol/L) for 1 hour, followed by stimulation with LPS at 1 μg/mL for 2 hours, ahead of which the PI3K inhibitor LY294002 has been added and then the protein was harvested. The expression of signaling molecules was detected by western blot. (A): LPS induced TF expression is attenuated by bradykinin, which is blocked by PI3K inhibitor LY294002; (B): BK and LPS induced AKT phosphorylation under resting condition, and the AKT phosphorylation is blocked by LY294002; (C): LPS reduced the GSK3β phosphorylation and this is reversed by bradykinin preincubation, which is also inhibited by LY294002; (D-F): LPS activated MAPK (P38/JNK/ERK), and bradykinin suppressed this trend, which is interrupted by LY294002. The intensity of each band was quantified by densitometry and expressed as folds of untreated control cells Data are shown as means ±SEM of 3 independent experiments. * P < 0.05 vs control; # P < 0.05 vs LPS;
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry and moreover PI3K, phosphor-AKT and phosphor-GSK-3β level were also abolished by HOE-140 treatment ( Fig. 5 and 6 ). Additionally, bradykinin B2 receptor activation leads to the release of NO [28] , we also investigated whether NO was involved in the beneficial effects of bradykinin on TF expression. N-methyl-L-arginine acetate salt (L-NAME 10 μmol/L) treatment totally blocked the beneficial effect of bradykinin on TF expression, and moreover PI3K, phosphor-AKT and phosphor-GSK-3β level were also abolished by L-NAME treatment ( Fig. 5 and 6 ). These data suggested that NO was the upstream target of PI3K/AKT signaling pathway, which was involved in the inhibitory effects of bradykinin on TF expression. Collectively, these results indicated that bradykinin inhibited HUVECs and monocytes TF expression induced by LPS via activation of eNOS-NO-PI3K/AKT-ERK signaling pathways.
Bradykinin restrains thrombosis by reducing tissue factor expression induced by inflammation.
TF is also involved in the formation of deep vein thrombosis [29] . Using a mouse model of deep vein thrombosis, we explored whether bradykinin could affect thrombus formation. We injected bradykinin intraperitoneally into C57BL/6J mice for three days before ligation of inferior vena cava, and injection of bradykinin was continued for another 2 days after surgical procedure until sacrifice. Interestingly, Mice treated with vehicle had large thrombi in their inferior vena cava, whereas mice treated with bradykinin had very small thrombi in their ligated inferior vena cava as shown in Fig. 7A . This beneficial effect was further confirmed by reduced TF activity and TF mRNA ( Fig. 7B and C) in thrombi and fibrin expression in liver (Fig. 7D) . The coagulation factor, TF, plays a pivotal role in the formation of deep vein thrombosis. Bradykinin treatment markedly reduced TF expression in thrombi as shown in Fig. 7E . Interestingly, the level of other inflammatory factors (P-selectin, VCAM-1, ICAM-1) in thrombi of mice treated with bradykinin was significantly lower than that treated with vehicle (Fig.  7E ). These data indicated that exogenous bradykinin significantly inhibited macrophage derived TF expression and myeloid cells adhesion to the vessel wall via reduced P-selectin, VCAM-1 and ICAM-1 expression. Meanwhile, the P13K/AKT expression in the vascular wall is also elevated (Fig. 7F and 7G ), which again prove the involvement of the PI3K/AKT signaling pathway in the regulation of tissue factor expression. 
Discussion
In the present study, our data demonstrated that bradykinin inhibited TF expression in endothelial cells and in monocytes/macrophages via activation of the eNOS PI3K/Akt signaling pathway. PI3K/Akt signaling pathway reduced the activity of MAPK and GSK-3β, and suppressed NF-kB transcriptional activity, thereby inhibiting TF expression. Importantly, exogenous bradykinin attenuated deep vein thrombosis via reduced TF expression and myeloid cells adhesion to the vessel wall in the mouse model.
Previous studies have demonstrated that the cytokines are intimately associated with TF expression and thrombus formation [30] . Leukocytes can be tethered to P-or E-selectin expressed on activated endothelial cells, and such interactions can promote the transfer of TF to induce thrombosis [9, 26] . Monocytes are the primary source of TF in the stasis induced thrombus formation although endothelial cells also express some TF [31] . LPS treatment could also stimulate TF expression in human umbilical vein endothelial cells and -methyl-L-arginine acetate salt (L-NAME) (10 μmol/l) were added 30 minutes before BK treatment, after which BK was added without replacing the medium.6 hours after LPS treatment, cells were harvested for detection. (A): bradykinin suppressed LPS induced TF expression, and this effect is almost completely blocked by HOE-140 and L-NAME, while PI3K exhibit an opposite expression; (B)-(C): bradykinin reversed LPS reduced AKT and GAK3β phosphorylation, which was restrained by HOE-140 and L-NAME. At least 3 separate experiments were performed per treatment. Data are shown as means ± SEM of 3 independent experiments. * P < 0.05 vs control; # P < 0.05 vs LPS;
human peripheral blood monocytes [29] . Kallikrein treatment through kinin B2 receptor activation reduced MAPK and Ikappa-Balpha phosphorylation, NF-kB activation and MCP-1 and VCAM-1 expression [29] . In this study, bradykinin exhibited a consistent inhibitory effect on LPS induced TF protein expression in both monocytes and HUVECs in a dose dependent fashion. Moreover, bradykinin treatment also decreased plasma TF level and reduced deep vein thrombosis in mice treated with ligation of inferior vena cava. Under inflammatory conditions, activated endothelial cells heighten the expression of cell adhesion molecules (CAM), including ICAM-1, VCAM-1, and P-selectin. Leukocytes attach to activated endothelial cells via adhesion molecules which interact with their ligands present on the leukocytes [25, 32] . A number of studies have shown that engagement and cross-linking of the counter receptors for several adhesion molecules, such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin, and P-selectin, will result in transcription of the TF gene and subsequent surface expression of the protein [26, 33] . Previous studies have shown that interference with both P-selectin and E-selectin should have a beneficial effect on decreasing clot formation during venous thrombosis [34] . Interestingly, in the present study, bradykinin inhibited the LPS-induced expression of pro-inflamatory mediators such as TNF-α, IL-1β, P-selectin and E-selectin in endothelial cells, as well as monocytes activation characterized by inflammatory cytokines expression, which indicated that exogenous bradykinin inhibited the adhesion of leukocytes to the endothelium. It is also speculated that bradykinin inhibited TF expression via reduced adhesion molecules expression, and thus broke the vicious circle in the deep vein thrombosis. Collectively, these data demonstrated that exogenous bradykinin prevented deep vein thrombosis via reduced monocytes and HUVECs TF expression and adhesion of leukocytes to the endothelium. Furthermore, the angiotensin-converting enzyme breakdown product of bradykinin, Arg-Pro-Pro-Gly-Phe (RPPGF), is a stable metabolite of bradykinin [35, 36] , and this peptide has biological activity [37] . Further study indicated that RPPGF inhibited both α-and β-thrombin-induced platelet aggregation and secretion via binding to the active site of thrombin and the extracellular domain of PAR1 to prevent thrombin cleavage after Arg41 [18, 38] . Thus, it is speculated that the inhibitory effects of bradykinin metabolite RPPGF on both α-and β-thrombin-induced platelet aggregation and secretion may be partly involved in the beneficial effects of bradykinin on deep vein thrombosis. In addition, the rapid development of DVT after IVC ligation reflects a combination of stasis-induced vein wall injury and enhanced TF expression in endothelial cells and leukocytes [9] . Furthermore, once venous thrombosis begins, an acute to chronic inflammatory response occurs in the thrombus and vein wall which leads to thrombus amplification. Proinflammatory cytokines such as TNF-α and IL-1β were indeed increased at the occlusion site, which are potent inducer of monocyte-derived TF-bearing micro vesicles. TF-bearing micro vesicles are central in the pathogenesis of DVT in disease states in which monocytes are stimulated to express TF [11] . Whether bradykinin inhibited deep vein thrombosis via reduced TF-bearing micro vesicles level and activity remains to be further elucidated.
The p38MAPK, p44/42MAPK, and c-jun terminal NH2-kinase (JNK) are involved in LPS-induced, TNF-α induced, histamine-induced, and thrombin-induced TF expression [39] . These signal transduction molecules stimulate the TF promoter by activating transcription factors such as nuclear factor (NF)-κB, ultimately resulting in up-regulation of TF mRNA [40] . Unlike MAP kinases, however, the PI3-kinase pathway negatively regulates TF expression [29, 31] . Bradykinin limited myocardial infarction induced by ischemia-reperfusion injury via PI3K/Akt/eNOS signaling pathway in mouse heart [29] . Bradykinin inhibited oxidative stress-induced cardiomyocytes senescence by acting through BK B2 receptor induced NO release [14] . In this study, the PI3K inhibitor LY294002 blocked the activation of Akt by bradykinin, and thus abolished the inhibitory effects of bradykinin on tissue factor expression. HOE-140 administration totally blocked the beneficial effect of bradykinin on TF expression, and moreover PI3K, phosphor-AKT and GSK-3β level were also abolished by HOE-140 treatment. Additionally, N-methyl-L-arginine acetate salt (L-NAME 10 μmol/L) treatment totally blocked the beneficial effect of bradykinin on TF expression, and moreover PI3K, phosphor-AKT and GSK-3β level were also abolished by L-NAME treatment. Exogenous bradykinin inhibited NF-kB translocation to the neucleus, concomitantly with the inhibition of TF. These data indicated that bradykinin inhibited TF expression via activating BK B2 receptor/eNOS/PI3K/AKT/GSK-3β/NF-kB signaling pathway. However, B2R makes a complex with eNOS, and L-NAME may bind eNOS inhibiting BK binding to B2R. Thus whether this point was involved in this study remains unkown, and it warrants further investigation.
In addition, there exists a cross-talk between the MAPK and the PI3K pathway on LPSinduced TF expression [41] , our in vitro studies indicated that major targets of the PI3K-Akt pathways were the MAPK pathways. Inhibition of the PI3K-Akt pathway was likely to enhance LPS induced activation of the MAPK pathway and the subsequent expression of proinflammatory and procoagulant molecules. The PI3K-Akt pathway also inhibited NF-κB activity [31] . Thus drugs targeting the activation of the PI3K-Akt pathway may limit LPSinduced TF expression and thrombus formation. However, some other studies indicate that
